Reduction of adverse events after percutaneous intervention...

Details Reduction of adverse events after percutaneous intervention... Reduction of adverse events after percutaneous intervention...

A - Human Necessities

61

K

A61K 31/443 (2006.01) A61P 9/10 (2006.01)

Patent

CA 2681597

Disclosed are methods of preventing adverse clinical events in a patient undergoing a percutaneous coronary intervention procedure or a peripheral percutaneous interventional procedure comprising administering a therapeutically effective amount of a thrombin receptor antagonist, such as SCH 530348, to the patient. Administration of a loading dose of about 40 mg of SCH 530348 in as little as one hour prior to the procedure can result in therapeutically effective levels of platelet aggregation.

L'invention concerne des procédés de prévention d'événements cliniques indésirables chez un patient subissant une procédure d'intervention coronarienne percutanée ou une procédure d'intervention percutanée périphérique comprenant l'administration d'une quantité thérapeutiquement efficace d'un antagoniste du récepteur de thrombine, tel que le SCH 530348, au patient. L'administration d'une dose de charge d'environ 40 mg de SCH 530348 dans un temps aussi court qu'une heure avant la procédure peut conduire à des taux thérapeutiquement efficaces d'agrégation plaquettaire.

Affiliated with

Also associated with

Rating

Reduction of adverse events after percutaneous intervention... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Reduction of adverse events after percutaneous intervention..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Reduction of adverse events after percutaneous intervention... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1915276